Not known Facts About YX-2-107
MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage multiple intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Main trial goals have been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis ind